Recombinant protein therapeutics - success rates, market trends and values to 2010

Article Abstract:

The success rates and market trends in recombinant deoxyribo nucleic acid (rDNA) protein for the period 2004 to 2010 are studied. It is seen that the recombinant protein sector is expected to drive the growth of medical biotechnology over the coming years and the rDNA therapeutics market's value could grow from $34,807m in 2004 to $41,744m in 2006 and then to $52,150m in 2010.

Forecasts, trends, outlooks, Sales & consumption, Drugs, Analysis, Biotechnology industry, Biotechnology industries, Forecasts and trends, Market trend/market analysis, Recombinant proteins, Market size, Industry forecasts

---

Monoclonal antibodies in the clinic

Article Abstract:

Early on, monoclonal antibodies (mAbs) were touted as being able to cure many diseases. Recent clinical trials have shown that improved strains of mAbs are indeed effective. Ten mAbs have been approved by the FDA, and 70 are in clinical trials.

United States, Science & research, Biological Product (except Diagnostic) Manufacturing, Regulation of Agricultural Marketing and Commodities, Food & Drug Administration, Biological products exc. diagnostic, Regulation of agricultural marketing, Monoclonal Antibodies for Therapeutics, Therapeutics, Monoclonal antibodies

---

Similar abstracts:

• Abstracts: Tune up those rock pitches. George Polk Awards names top stories for 2005. 'Give us an expert', financial editors say
• Abstracts: Interdependencies between marketing and public relations disciplines as correlates of communication organisation
• Abstracts: Product attribute-based voter segmentation and resource advantage theory. part 2 Political parties, the internet and the 2005 General Election: from web presence to e-campaigning?
• Abstracts: Forward/up directional incompatibilities during cursor placement within graphical user interfaces. Characteristics of cursor trajectories controlled by the computer mouse
• Abstracts: The effect of audit committee shareholding, financial expertise and size of interim financial disclosures. The distribution of earnings relative to targets in the European Union

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.